Abstract：Objective: To observe the changes in neutrophil/lymphocyte ratio (NLR) and CD4+/CD8+ in patients with lung cancer after treatment with programmed death receptor-1 (PD-1) inhibitor, and to analyze the correlation between changes of two indicators and efficacy and overall survival time (OS).Methods: A total of 94 patients with pulmonary cancer were included in the hospital from December 2019 to March 2022. The changes of NLR and CD4+/CD8+ were observed among patients with different efficacies after PD-1 treatment, and the association with different efficacies after immunotherapy and OS after 2 years of follow-up was analyzed.Results: There were statistically significant differences in NLR and CD4+/CD8+ among patients with different efficacies after PD-1 inhibitor treatment (P<0.05). The NLR and CD4+/CD8+ in the CR group and PR group were statistically different from those in the SD group and CD group (P<0.05), and there was a statistical significance in NLR between the SD group and PD group (P<0.05). Univariate analysis showed that the pathological type, TNM staging, differentiation degree, age, NLR and CD4+/CD8+ were statistically significant between the effective group and the ineffective group after immunotherapy (P<0.05). Logistic regression model found that small cell type, TNM staging (stage IV), differentiation degree (low differentiation), older age, and high NLR were risk factors for poor efficacy of immunotherapy (P<0.05), while high CD4+/CD8+ was a protective factor for poor efficacy of immunotherapy (P<0.05). ROC curve showed that the areas under the curves (AUCs) of NLR and CD4+/CD8+ in evaluating the efficacy were 0.785 and 0.777 respectively, and the AUC of NLR combined with CD4+/CD8+ was 0.871, which was significantly higher than that of single index (P<0.05). Spearman correlation analysis suggested that NLR was negatively correlated with OS (r=-0.341, P<0.05), and CD4+/CD8+ was positively correlated with OS (r=0.323, P<0.05).Conclusion: The NLR is lower while the CD4+/CD8+ is higher among patients with pulmonary cancer who are with effective PD-1 inhibitor treatment, and the two indexes have certain evaluated values on the efficacy of immunotherapy and also have a certain association with OS.
吕志芳, 王明, 程飞飞, 王玲, 钱建伟. 中性粒细胞/淋巴细胞CD4+/CD8+与PD-1抑制剂免疫治疗肺癌疗效及OS的关系研究[J]. 河北医学, 2024, 30(9): 1483-1487.
LV Zhifang, WANG Ming, CHENG Feifei, et al. Study on the Relationship between Neutrophils/Lymphocytes CD4+/CD8+ and the Efficacy and OS of PD-1 Inhibitor Immunotherapy for Lung Cancer. HeBei Med, 2024, 30(9): 1483-1487.
2024, Vol. 30 
冀公网安备13080202000786号